McKesson Raises Forecast and Records Share Price Increase

The stock of healthcare provider McKesson experienced a remarkable increase of 6.6% in early trading after the company raised its earnings forecast for the fiscal year 2026 during its 2025 Investor Day and upgraded its long-term growth targets. McKesson's leadership presented a new forecast for adjusted earnings per share for fiscal 2026, setting it in the range of $38.05 to $38.55. This forecast not only surpasses previous estimates but also the market expectations. Additionally, the long-term growth of adjusted earnings was increased to 13% to 16%, compared to the previous target of 12% to 14%. This positive adjustment is particularly attributed to the strength of platforms in the oncology and biopharma solutions sectors, considered central drivers for this more optimistic outlook. This indicates the company's targeted focus on more profitable business segments. Interestingly, McKesson's stock showed few movements of more than 5% over the past year. The current market reaction underscores the relevance of the current news, even though it does not fundamentally change the perception of the company. Moreover, McKesson had already seen a stock gain 12 days ago following the announcement of a deal with Walmart and USAntibiotics. This agreement establishes McKesson as the national distributor for the USA-made antibiotic Amoxicillin, thereby strengthening its position within the critical national supply chain. With a price increase of 31.6% since the beginning of the year, McKesson reached a new 52-week high at a stock price of $745.34. Investors who purchased McKesson shares for $1,000 five years ago would today hold an investment worth $5,067. For young investors seeking the new "gorillas" in the technology sector, opportunities are available in software stocks that leverage their potential through generative AI. These companies could be the future winners in the enterprise software domain and are the focus of a special free report.